| Original language | English |
|---|---|
| Pages (from-to) | 1813-1815 |
| Number of pages | 3 |
| Journal | JAMA - Journal of the American Medical Association |
| Volume | 320 |
| Issue number | 17 |
| DOIs | |
| State | Published - 6 Nov 2018 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Evaluation of Lowering the P Value Threshold for Statistical Significance From.05 to.005 in Previously Published Randomized Clinical Trials in Major Medical Journals. / Wayant, Cole; Scott, Jared; Vassar, Matt.
In: JAMA - Journal of the American Medical Association, Vol. 320, No. 17, 06.11.2018, p. 1813-1815.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Evaluation of Lowering the P Value Threshold for Statistical Significance From.05 to.005 in Previously Published Randomized Clinical Trials in Major Medical Journals
AU - Wayant, Cole
AU - Scott, Jared
AU - Vassar, Matt
N1 - Funding Information: Funding/Support: This study was supported in part by a contract from the European Commission Directorate-General for Health and Consumers Protection (SANCO/2014/C2/035) and an unrestricted grant from the Lundbeck Foundation (iPSYCH). Funding Information: Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Berk reported receiving grants from the Australian National Health and Medical Research Council Senior Principal Research Fellowship, Stanley Medical Research Foundation, Medical Benefits Fund of Australia Ltd, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Rotary Health, Meat and Livestock Board, Woolworths, BeyondBlue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; receiving personal fees from Lundbeck, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Servier, AstraZeneca, Pfizer, Sanofi Synthelabo, Solvay, Wyeth, Bioadvantex, Merck, and Janssen Cilag; and having a number of patents pending for agents for psychiatric or central nervous system disorders. No other disclosures were reported.
PY - 2018/11/6
Y1 - 2018/11/6
UR - http://www.scopus.com/inward/record.url?scp=85056081348&partnerID=8YFLogxK
U2 - 10.1001/jama.2018.12288
DO - 10.1001/jama.2018.12288
M3 - Letter
C2 - 30398593
AN - SCOPUS:85056081348
VL - 320
SP - 1813
EP - 1815
JO - Journal of the American Medical Association
JF - Journal of the American Medical Association
SN - 0098-7484
IS - 17
ER -